Inventiva SA
PAR:IVA
Inventiva SA
Total Liabilities & Equity
Inventiva SA
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Inventiva SA
PAR:IVA
|
Total Liabilities & Equity
€39.4m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Total Liabilities & Equity
€500m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
|
Nanobiotix SA
PAR:NANO
|
Total Liabilities & Equity
€86.7m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
3%
|
CAGR 10-Years
11%
|
|
|
Innate Pharma SA
PAR:IPH
|
Total Liabilities & Equity
€111.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
2%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Total Liabilities & Equity
€194.8m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
10%
|
|
|
Eurobio Scientific SA
PAR:ALERS
|
Total Liabilities & Equity
€313.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
34%
|
CAGR 10-Years
22%
|
|
Inventiva SA
Glance View
Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. The company is headquartered in Daix, Occitanie and currently employs 100 full-time employees. The company went IPO on 2017-02-15. The firm focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The Company’s pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of non-alcoholic steatohepatitis (NASH), systemic sclerosis (SSc), various types of mucopolysaccharidosis (MPS), multiple myeloma, auto-immune disorders, as well as lung cancer, among others. In addition, the Company offers drug discovery services, ranging from target identification to preclinical nomination, in numerous areas, such as silico modelling, biology, screening, absorption, distribution, metabolism and excretion (ADME), pharmacology and histology.
See Also
What is Inventiva SA's Total Liabilities & Equity?
Total Liabilities & Equity
39.4m
EUR
Based on the financial report for Dec 31, 2024, Inventiva SA's Total Liabilities & Equity amounts to 39.4m EUR.
What is Inventiva SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-7%
Over the last year, the Total Liabilities & Equity growth was -43%. The average annual Total Liabilities & Equity growth rates for Inventiva SA have been -31% over the past three years , -7% over the past five years .
You don't have any saved screeners yet